# APOE

## Overview
The APOE gene encodes apolipoprotein E, a critical protein involved in lipid metabolism and transport. Apolipoprotein E is a glycoprotein that plays a significant role in the clearance of plasma lipoproteins and is essential for maintaining lipid homeostasis in both peripheral tissues and the central nervous system. It is categorized as a lipid-binding protein due to its involvement in the transport and metabolism of lipids. The APOE gene is located on chromosome 19 and exists in three major isoforms: E2, E3, and E4, which differ by single amino acid substitutions and have distinct functional implications. These isoforms influence the protein's role in lipid metabolism and its interaction with amyloid-beta peptides, which is particularly relevant in the context of Alzheimer's disease. The ε4 allele of APOE is a well-established genetic risk factor for late-onset Alzheimer's disease, while the ε2 allele is considered protective against the disease (Davignon1999Apolipoprotein; SerranoPozo2021APOE).

## Structure
Apolipoprotein E (APOE) is a protein with a primary structure consisting of 299 amino acids, located on chromosome 19. The gene comprises four exons and three introns (Weisgraber1994Apolipoprotein). The secondary structure of APOE is predominantly alpha-helical, with the protein forming a four-helix bundle in its NH2-terminal domain. This domain is elongated, measuring approximately 65 Å in length, and is stabilized by a hydrophobic core and numerous salt bridges (Weisgraber1994Apolipoprotein; Wilson1991ThreeDimensional).

The NH2-terminal domain, which spans residues 20-165, is highly stable and responsible for receptor binding, particularly involving helix 4 (residues 136-150) (Wilson1991ThreeDimensional; Wetterau1988Human). The COOH-terminal domain, encompassing residues 225-299, is less stable and involved in lipid binding and tetramerization (Weisgraber1994Apolipoprotein).

APOE exists in three major isoforms: E2, E3, and E4, which differ by single amino acid substitutions and have functional differences affecting lipid metabolism (Hatters2006Apolipoprotein). The protein undergoes post-translational modifications, including glycosylation and phosphorylation, which can influence its function and interactions (Hatters2006Apolipoprotein).

## Function
Apolipoprotein E (apoE) is a glycoprotein encoded by the APOE gene, playing a crucial role in lipid metabolism and cardiovascular health. It is involved in the receptor-mediated clearance of plasma lipoproteins, including very low-density lipoproteins (VLDL), high-density lipoproteins (HDL), and chylomicrons, facilitating the uptake of triglyceride-rich lipoproteins and maintaining macrophage lipid homeostasis (Davignon1999Apolipoprotein). ApoE promotes reverse cholesterol transport by enhancing cholesterol efflux from macrophages and stimulating the hepatic uptake of lipoproteins, which is essential for maintaining lipid homeostasis (Kockx2018Cellspecific; Davignon1999Apolipoprotein).

In the central nervous system, apoE is primarily secreted by astrocytes and plays a vital role in lipid transport, delivering cholesterol and phospholipids to neurons, and maintaining brain integrity (Kockx2018Cellspecific). It also influences synaptogenesis and synaptic maintenance, supporting cognitive functions (Holtzman2012Apolipoprotein). ApoE exhibits antioxidant properties, inhibits platelet aggregation, and modulates immune function, contributing to its anti-atherogenic effects (Davignon1999Apolipoprotein). The protein's function is modulated by cellular cholesterol status and is influenced by various factors, including cytokines and hormones (Kockx2018Cellspecific).

## Clinical Significance
The APOE gene, particularly its ε4 allele, is a significant genetic risk factor for late-onset Alzheimer's disease (AD). Individuals carrying one or two copies of the ε4 allele have an increased risk of developing AD and tend to experience an earlier onset of the disease. This allele is associated with impaired clearance of amyloid-beta (Aβ), leading to increased amyloid plaque burden and contributing to AD pathogenesis (Liu2013Apolipoprotein; SerranoPozo2021APOE). The ε4 allele is also linked to more severe tau pathology and neurodegeneration, exacerbating cognitive decline (SerranoPozo2021APOE).

In addition to Alzheimer's disease, the ε4 allele is associated with other neurodegenerative conditions, such as cerebral amyloid angiopathy, which increases the risk of intracerebral hemorrhage, and is implicated in synaptic dysfunction and neuroinflammation (Fernández-Calle2022APOE; SerranoPozo2021APOE). The ε4 allele is also linked to cardiovascular diseases, including atherosclerosis and coronary heart disease, due to its effects on lipid metabolism (Liu2013Apolipoprotein).

Conversely, the ε2 allele of APOE is considered protective against Alzheimer's disease, associated with a lower burden of amyloid plaques and tau pathology, although it may increase the risk of certain tauopathies (Fernández-Calle2022APOE; SerranoPozo2021APOE).

## Interactions
Apolipoprotein E (APOE) is involved in several critical interactions, particularly with amyloid-beta (Aβ) peptides, which are significant in the context of Alzheimer's disease. APOE binds to Aβ peptides with high avidity, and this interaction is isoform-specific, with the APOE4 isoform showing a faster and more efficient binding compared to APOE3. This binding leads to the formation of stable complexes, which are implicated in the pathogenesis of Alzheimer's disease (Strittmatter1993Binding; Sanan1994Apolipoprotein).

The APOE/Aβ complex formation is influenced by factors such as pH and the lipidation state of APOE. APOE4-containing lipoproteins are less lipidated, resulting in less stable complexes and increased levels of soluble oligomeric Aβ, which are neurotoxic (Tai2014Soluble). Despite these interactions, studies have shown that under physiological conditions, the association of APOE with Aβ in cerebrospinal fluid is minimal, suggesting that APOE does not significantly bind to Aβ in vivo (Verghese2013ApoE).

APOE also interacts with low-density lipoprotein receptor-related protein 1 (LRP1), which is involved in the clearance of soluble Aβ. This interaction suggests that APOE may compete with Aβ for the same clearance pathways, affecting Aβ uptake and clearance (Verghese2013ApoE).


## References


[1. (Tai2014Soluble) Leon M Tai, Shipra Mehra, Varsha Shete, Steve Estus, G William Rebeck, Guojun Bu, and Mary Jo LaDu. Soluble apoe/aβ complex: mechanism and therapeutic target for apoe4-induced ad risk. Molecular Neurodegeneration, January 2014. URL: http://dx.doi.org/10.1186/1750-1326-9-2, doi:10.1186/1750-1326-9-2. This article has 89 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1750-1326-9-2)

[2. (Weisgraber1994Apolipoprotein) Karl H. Weisgraber. Apolipoprotein E: Structure-Function Relationships, pages 249–302. Elsevier, 1994. URL: http://dx.doi.org/10.1016/S0065-3233(08)60642-7, doi:10.1016/s0065-3233(08)60642-7. This article has 1093 citations.](https://doi.org/10.1016/S0065-3233(08)60642-7)

[3. (Davignon1999Apolipoprotein) Jean Davignon, Jeffrey S. Cohn, Laurence Mabile, and Lise Bernier. Apolipoprotein e and atherosclerosis: insight from animal and human studies. Clinica Chimica Acta, 286(1–2):115–143, August 1999. URL: http://dx.doi.org/10.1016/s0009-8981(99)00097-2, doi:10.1016/s0009-8981(99)00097-2. This article has 159 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0009-8981(99)00097-2)

[4. (SerranoPozo2021APOE) Alberto Serrano-Pozo, Sudeshna Das, and Bradley T Hyman. Apoe and alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology, 20(1):68–80, January 2021. URL: http://dx.doi.org/10.1016/s1474-4422(20)30412-9, doi:10.1016/s1474-4422(20)30412-9. This article has 470 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s1474-4422(20)30412-9)

[5. (Hatters2006Apolipoprotein) Danny M. Hatters, Clare A. Peters-Libeu, and Karl H. Weisgraber. Apolipoprotein e structure: insights into function. Trends in Biochemical Sciences, 31(8):445–454, August 2006. URL: http://dx.doi.org/10.1016/J.TIBS.2006.06.008, doi:10.1016/j.tibs.2006.06.008. This article has 728 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/J.TIBS.2006.06.008)

[6. (Verghese2013ApoE) Philip B. Verghese, Joseph M. Castellano, Kanchan Garai, Yinong Wang, Hong Jiang, Aarti Shah, Guojun Bu, Carl Frieden, and David M. Holtzman. Apoe influences amyloid-β (aβ) clearance despite minimal apoe/aβ association in physiological conditions. Proceedings of the National Academy of Sciences, April 2013. URL: http://dx.doi.org/10.1073/pnas.1220484110, doi:10.1073/pnas.1220484110. This article has 420 citations.](https://doi.org/10.1073/pnas.1220484110)

[7. (Holtzman2012Apolipoprotein) D. M. Holtzman, J. Herz, and G. Bu. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(3):a006312–a006312, January 2012. URL: http://dx.doi.org/10.1101/cshperspect.a006312, doi:10.1101/cshperspect.a006312. This article has 559 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a006312)

[8. (Fernández-Calle2022APOE) Rosalía Fernández-Calle, Sabine C. Konings, Javier Frontiñán-Rubio, Juan García-Revilla, Lluís Camprubí-Ferrer, Martina Svensson, Isak Martinson, Antonio Boza-Serrano, José Luís Venero, Henrietta M. Nielsen, Gunnar K. Gouras, and Tomas Deierborg. Apoe in the bullseye of neurodegenerative diseases: impact of the apoe genotype in alzheimer’s disease pathology and brain diseases. Molecular Neurodegeneration, September 2022. URL: http://dx.doi.org/10.1186/s13024-022-00566-4, doi:10.1186/s13024-022-00566-4. This article has 104 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13024-022-00566-4)

[9. (Liu2013Apolipoprotein) Chia-Chen Liu, Takahisa Kanekiyo, Huaxi Xu, and Guojun Bu. Apolipoprotein e and alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 9(2):106–118, January 2013. URL: http://dx.doi.org/10.1038/nrneurol.2012.263, doi:10.1038/nrneurol.2012.263. This article has 2395 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nrneurol.2012.263)

[10. (Strittmatter1993Binding) W J Strittmatter, K H Weisgraber, D Y Huang, L M Dong, G S Salvesen, M Pericak-Vance, D Schmechel, A M Saunders, D Goldgaber, and A D Roses. Binding of human apolipoprotein e to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset alzheimer disease. Proceedings of the National Academy of Sciences, 90(17):8098–8102, September 1993. URL: http://dx.doi.org/10.1073/pnas.90.17.8098, doi:10.1073/pnas.90.17.8098. This article has 955 citations.](https://doi.org/10.1073/pnas.90.17.8098)

[11. (Wilson1991ThreeDimensional) Charles Wilson, Mark R. Wardell, Karl H. Weisgraber, Robert W. Mahley, and David A. Agard. Three-dimensional structure of the ldl receptor-binding domain of human apolipoprotein e. Science, 252(5014):1817–1822, June 1991. URL: http://dx.doi.org/10.1126/science.2063194, doi:10.1126/science.2063194. This article has 536 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.2063194)

[12. (Sanan1994Apolipoprotein) D A Sanan, K H Weisgraber, S J Russell, R W Mahley, D Huang, A Saunders, D Schmechel, T Wisniewski, B Frangione, and A D Roses. Apolipoprotein e associates with beta amyloid peptide of alzheimer’s disease to form novel monofibrils. isoform apoe4 associates more efficiently than apoe3. Journal of Clinical Investigation, 94(2):860–869, August 1994. URL: http://dx.doi.org/10.1172/jci117407, doi:10.1172/jci117407. This article has 306 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci117407)

[13. (Kockx2018Cellspecific) Maaike Kockx, Mathew Traini, and Leonard Kritharides. Cell-specific production, secretion, and function of apolipoprotein e. Journal of Molecular Medicine, 96(5):361–371, March 2018. URL: http://dx.doi.org/10.1007/s00109-018-1632-y, doi:10.1007/s00109-018-1632-y. This article has 72 citations.](https://doi.org/10.1007/s00109-018-1632-y)

[14. (Wetterau1988Human) J R Wetterau, L P Aggerbeck, S C Rall, and K H Weisgraber. Human apolipoprotein e3 in aqueous solution. i. evidence for two structural domains. Journal of Biological Chemistry, 263(13):6240–6248, May 1988. URL: http://dx.doi.org/10.1016/s0021-9258(18)68778-2, doi:10.1016/s0021-9258(18)68778-2. This article has 233 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)68778-2)